Skip to main content

Table 2 Patient characteristics stratified by warfarin use

From: Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study

Characteristic

All (n = 35)

Warfarin user (n = 12)

Non-warfarin user (n = 23)

Age (years)

61 (51–77)

65.5 (52.5–79)

59 (51–74)

Male

25 (71%)

8 (67%)

17 (74%)

PT-INR at trough

1.39 (1.12–2.38)

2.62 (1.63–3.29)

1.19 (1.06–1.42)

Time interval between trough and peak (min)

105 (95–120)

95 (95–110)

112.5 (90–120)

Daptomycin dose (mg/kg/dose)

6.0 (5.9–6.1)

6.0 (5.9–6.4)

6.0 (5.8–6.0)

Number of daptomycin administered before peak

4 (3–5)

4.5 (4–5.5)

4 (3–5)

Creatinine clearance (mL/min)

84.8 ± 54.1

74.2 ± 40.4

89.9 ± 59.7

Source of infection

 Skin/joint infection

19 (54%)

7 (58%)

12 (52%)

 Bacteraemia

12 (34%)

5 (42%)

7 (30%)

 Other infections

4 (11%)

0 (0%)

4 (17%)

Comorbidity

 Autoimmune disease

5 (14%)

2 (17%)

3 (13%)

 Cancer

6 (17%)

2 (17%)

4 (17%)

 Cardiovascular disease

13 (37%)

8 (67%)

5 (22%)

 Others

11 (31%)

0 (0%)

11 (48%)

Concomitant antibiotic use

17 (49%)

7 (58%)

10 (43%)

  1. Data are shown as a number (%), mean ± standard deviation or median (interquartile range)
  2. PT-INR prothrombin time-international normalised ratio. PT-INR by Reagent 1 is shown